Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy

NCT01874353 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01874353
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01874353 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 3, 2013
Completion date
December 31, 2026
Enrollment
327 (actual)
Sites
126

Conditions

As the registry lists them; a condition with its own page is linked.

brca mutated, following complete or partial response to platinum based chemotherapy, platinum sensitive, relapsed ovarian cancer